---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-25-000276"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:39:13.866571+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Guardant Health Q3 revenue $265.2M (+39% YoY); raises FY2025 revenue guidance to $965-$970M

## Summary
- Q3 total revenue $265.2M (+39% YoY); GAAP net loss $92.7M ($0.74/share), non-GAAP net loss $48.3M ($0.39/share).
- Oncology revenue $184.4M (+31%), 74K tests (+40%); Shield screening revenue $24.1M (from $1M), 24K tests.
- FY2025 revenue guidance raised to $965-$970M (from $915-$925M), ~31% YoY growth; Screening rev guidance $71-$73M.
- Non-GAAP gross margin 66% (up from 63%); cash, equivalents and restricted cash $689.5M.
- Shield expanded to multi-cancer detection; Guardant360 Liquid PMA submitted to FDA; new collaborations with Quest and PathGroup.

## SEC filing metadata
- accession: 0001576280-25-000276
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628025000276/0001576280-25-000276-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628025000276/gh-20251029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-25-000276
- JSON: https://secwatch.observer/filing/0001576280-25-000276.json
- Plain text: https://secwatch.observer/filing/0001576280-25-000276.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.